Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
Research | 10 days ago |

Buzz on the Bullboards: Despite energy woes, TSX hits new high

This week, the TSX endured fluctuations but ultimately achieved a new high in intraday trading. The tech sector has been a significant driver of these gains, thanks to a solid performance among top stocks in the sector. One of Canada’s leading te...
Jonathon Brown | October 10, 2024 |

Revolutionary biopharma company makes waves across the globe

The following is a transcription of the above video, and The Market Online has edited it for clarity . The Market Online recently caught up with NurExone Biologic Inc (TSXV:NRX) , a revolutionary biopharmaceutical company developing regenerative medicine therapies,...
Lyndsay Malchuk | July 10, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Buzz on the Bullboards: Upbeat U.S. earnings good news for all?

Do rising tides truly lift all ships? We are in the midst of a strong earnings season and U.S. markets have reacted in kind. Strong earnings growth pushed Wall Street indices towards fresh record highs this past week. While activity moved lower earlier on, the belief ...
Jonathon Brown | February 8, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...
Jonathon Brown | January 25, 2024 |

ExoTherapy offers hope for treating acute spinal cord injuries

Suffering from traumatic injuries can leave a person with long-term damages and/or side effects that are hard to navigate long after the initial incident has passed. Our next company is a publicly traded bio-pharmaceutical company, working on the development of its ...
Brieanna McCutcheon | September 19, 2023 |

Buzz on the Bullboards: Summer's most talked about stocks

August has been a rough month for North American stock markets, with red days and a lot of flat trading activity. Shares of U.S. banks fell this week after several regional lenders were hit with a credit downgrade. Retailers are stuck with products that aren&CloseCurl...
Jonathon Brown | August 24, 2023 |

HAVN Life Sciences: a biotech company developing technology-focused, data-driven psychedelic therapi

HAVN Life Sciences is a biotech company focused on psychedelic therapies. The Vancouver-based company develops technology-focused, data-driven, and medical-based solutions. Joining us here at the Top Line today is HAVN Life Sciences CEO, Tim Moore. Welcome back a...
Simon Druker | March 30, 2023 |
1 2 3 4 5